Browse articles from EyeWorld.org related to AMD. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ First AI foundation model in ophthalmology ➤ 24-month topline data from Phase 3 geographic atrophy therapy ➤ Positive data from Phase 1/2 trial for retinitis pigmentosa, Leber congenital amaurosis treatment ➤ FDA clearance granted for portable retinal imaging system ➤ ASCRS news and events
➤ FDA issues eight warning letters ➤ Positive Phase 2 safety update for investigational treatment of retinal diseases ➤ First-in-human titratable glaucoma therapy system ➤ Companies partner to develop biological dry eye treatment ➤ Geographic atrophy drug development discontinued ➤ ASCRS news and events
➤ FDA issues complete response letter for bevacizumab for retinal diseases ➤ First patient dosed in study evaluating X-linked retinoschisis ➤ Gene therapy study for Leber hereditary optic neuropathy begins dosing ➤ Update on rare retinal vasculitis events associated with GA treatment ➤ Eye drop recall grows ➤ ASCRS news and events
➤ FDA approves high-dose aflibercept ➤ Positive results in Phase 1 trial for cultivated autologous limbal epithelial cells ➤ Study: data from eye scans detect Parkinson’s disease years before clinical presentation ➤ Phase 2/3 study to evaluate persistent corneal epithelial defect treatment ➤ Phase 3 study offers results with aflibercept biosimilar ➤ ASCRS news and events
➤ First implantations for clinical trials for investigational IOLs ➤ Phase 2 clinical trial for wet AMD treatment completes enrollment ➤ Two-year results from trial showcase vision gains in wet AMD at extended aflibercept dosing intervals ➤ Acquisition update ➤ ASCRS news and events
➤ Study: low-dose atropine doesn’t slow myopia progression ➤ Adverse events reported after use of FDA-approved geographic atrophy drug ➤ Phase 1 data for synthetic cannabinoid being investigated for glaucoma ➤ Enrollment complete in study evaluating topical diabetic retinopathy therapy ➤ Enrollment update for Phase 2b trial that could reduce AMD treatment burden ➤ ASCRS news and events
➤ Phase 1/2 trial to evaluate intravitreal implant to delay cataract progression ➤ Update from Phase 1/2 proof-of-concept trial for chronic TED treatment ➤ First patient dosed for investigational, oral geographic atrophy treatment ➤ Pediatric study for pain, inflammation treatment following ocular surgery ➤ Complimentary access to video journal ➤ ASCRS news and events
➤ Study evaluates safety of office-based lens surgery ➤ FDA issues response to BLA for 8 mg aflibercept ➤ Pre-clinical data for non-viral gene therapy ➤ Non-human primate study of dry AMD therapy ➤ Expanded insurance coverage for MIGS procedures ➤ ASCRS news and events
➤ Cataract surgery survey results ➤ FDA approves first non-degradable, synthetic tissue for ophthalmic surgery ➤ New cyclosporine ophthalmic solution approved for dry eye ➤ Results from Phase 2b study of drug-eluting contact lens ➤ 12-month topline data for intravitreal implant in wet AMD trial ➤ AAV capsid licensed for ocular gene therapy indication ➤ ASCRS news and events
➤ Phase 2 trial with experimental geographic atrophy treatment shows preservation of visual function ➤ AI-enabled screening system receives FDA clearance ➤ Enrollment complete for study evaluating investigational first-line therapy for DME ➤ Updates from two retinitis pigmentosa trials ➤ ASCRS news and events